drugset / Trial / NCT07211568

PERT in Acute Necrotizing Pancreatitis

NCT07211568

Phase 3 Not yet recruiting 188 enrolled Asian Institute of Gastroenterology, India
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, we propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). We will include patients of 18-60yrs age and both genders with \>50% pancreatic parenchymal necrosis and \>10% loss of body weight. The primary outcome measure is change in BMI at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.

Timeline

Start
2025-10-01
Primary completion
2027-04-30
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amylase Protein / enzyme biologic 18000 iu Oral
Subject Lipase Protein / enzyme biologic 25000 iu Oral
Subject Protease Protein / enzyme biologic 1000 iu Oral